Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

RTX001

PreclinicalSmall molecule

RResolution Therapeutics Limited

RTX001 is one of 22 small molecule programs targeting Liver. It is currently in Preclinical.

1

Indications

1

Total Trials

1

Active Trials

21

Competitors

Pipeline

Status by Indication[3][1]

Indication

LiverActive, not recruiting

LiverPreclinical

Active, not recruiting

Competition

Competitive Landscape

25 competitors in Liver

#DrugCompanyPhaseTrials

Sunlenca

Afinitor

Fetroja

Tygacil

PPrism Pharmaceuticals

Xerava

TTetraphase Pharmaceuticals, Inc

Azactam

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Pipracil

WWyeth-Lederle Vaccines

CAZ-AVI

Aztreonam-Avibactam

Meropenem-Vaborbactam

MMelinta Therapeutics, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalActive, not recruiting

Liver

NCT06823713

Clinical

Trials by Indication[1]

Liver1 trial

An Open-label Phase 1/2 Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of RTX001 Autologous Macrophages in Participants With Liver Cirrhosis Who Have Hepatic Decompensation (EMERALD)

Active, not recruiting·RResolution Therapeutics Limited·Preclinical·NCT06823713·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RTX001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RTX001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RTX001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Resolution Therapeutics Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RResolution Therapeutics Limited

Related News